Antiproteinuric Effects of Liraglutide Treatment

Sponsor
Steno Diabetes Center Copenhagen
Study ID
NCT02545738
Phase
PHASE4
Status
Completed

Conditions

  • Diabetic Kidney Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide — DRUG
    active treatment
  • placebo — DRUG
    placebo

Study Details

The purpose of the study is to determine the effect of Liraglutide on albuminuria in type 2 diabetes.

Key Dates

Start date
Apr 30, 2015
Status verified
Aug 2016
Primary completion
May 31, 2016
Completion
May 31, 2016

Study Design

Enrollment
32 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Liraglutide
    Liraglutide s.c. up-escalated to 1.8 mg/day for 12 weeks.
  • Placebo Comparator: Placebo
    Placebo s.c. for 12 weeks.

Primary Outcome Measure

Change in albuminuria [ Time Frame: 24 weeks ]

Related Studies